• metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
• mNSCLC - L2 - adenocarcinoma cell
• mNSCLC - L2 - all population 5
• mNSCLC - L2 - EGFR high
• mNSCLC - L2 - EGFR mutant 1
• mNSCLC - L2 - EGFR wild type
• mNSCLC - L2 - KRAS mutant
• mNSCLC - L2 - KRAS wild type
• mNSCLC - L2 - PDL1 negative 1
• mNSCLC - L2 - PDL1 positive 7
• non squamous cell - mNSCLC - L2
• non squamous - mNSCLC - L2 - all population 1
• non squamous - mNSCLC - L2 - EGFR mutant
• non squamous - mNSCLC - L2 - PDL1 positive
• non squamous - mNSCLC - L2 - wild type (WT)
• squamous cell - mNSCLC - L2
• squamous - mNSCLC - L2 - all population 1
• squamous - mNSCLC - L2 - PDL1 positive

 

• gene alteration target therapy
• BRAF gene alteration targeted therapy
• BRAF inhibitor
• combined BRAF-MEK inhibitors
• trametinib plus dabrafenib
• KRAS gene alteration targeted therapy
• sotorasib
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• durvalumab alone
• durvalumab plus osimertinib
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (2mg/kg)
• Tislelizumab
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs docetaxel
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs gene alteration target therapy
• vs EGFR gene alteration
• vs osimertinib
• vs non active control
• vs no control (uncontrolled study)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mNSCLC - L2 - all population;   mNSCLC - L2 - PDL1 positive;